Author: Capwell Communications

Posted Date:

April 30, 2026

JASMINE Trial Demonstrates Prolacta’s Human Milk-Based Fortifiers Deliver Superior Growth in Premature Infants While Maintaining Japan’s Renowned Low NEC Rate

Capwell Communications

April 30, 2026
Neuspera Medical Announces 12-Month Pivotal Trial Results for the Company’s Integrated Sacral Neuromodulation System for Urinary Urge Incontinence

Capwell Communications

March 5, 2026
A World-First in Neonatal Care: Japan Approves Prolacta Bioscience’s 100% Human Milk-Based Fortifiers as a Prescription Drug for Vulnerable Infants

Capwell Communications

February 19, 2026
A World-First in Neonatal Care: Japan Approves Prolacta Bioscience’s 100% Human Milk-Based Fortifiers as a Prescription Drug for Vulnerable Infants

Capwell Communications

February 18, 2026
Neuspera Medical Announces Milestone Case of Traditional Sacral Neuromodulation (SNM) System Removed and Replaced With the Company’s Integrated SNM System for Urinary Urge Incontinence

Capwell Communications

February 10, 2026